Vertex Pharmaceuticals Inc
Close on Nov 2, 2026Market cap $140.20BP/E 32.2Yield –
Vertex Pharmaceuticals Vertex Pharmaceuticals Limited by Year
Vertex Pharmaceuticals (Europe) Limited (UK 02907620, Ex-North America IP & Commercial Hub) — Turnover / Revenue ($M) ($M)
Vertex Pharmaceuticals Vertex Pharmaceuticals Limited: $12,784M in FY2025, up 1.0% from a year earlier. That is the highest of the 8 years on record here.
Where the FY2025 figure comes from
“Revenue 5 12,783,668 12,659,990”
Source: Vertex Pharmaceuticals (Europe) Limited (02907620) ↗
Reported in UK Companies House Audited Statutory Financial Statements (02907620, FY2018–FY2025, OCR).
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Vertex Pharmaceuticals (Europe) Limited (UK 02907620, Ex-North America IP & Commercial Hub) — Turnover / Revenue ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 12,784 | +1.0% | Vertex Pharmaceuticals (Europe) Limited (02907620) ↗ |
| FY2024 | Dec 31, 2024 | 12,660 | +30.6% | Vertex Pharmaceuticals (Europe) Limited (02907620) ↗ |
| FY2023 | Dec 31, 2023 | 9,690 | +15.3% | Vertex Pharmaceuticals (Europe) Limited (02907620) ↗ |
| FY2022 | Dec 31, 2022 | 8,408 | +15.2% | Vertex Pharmaceuticals (Europe) Limited (02907620) ↗ |
| FY2021 | Dec 31, 2021 | 7,301 | +2.4% | Vertex Pharmaceuticals (Europe) Limited (02907620) ↗ |
| FY2020 | Dec 31, 2020 | 7,128 | +48.5% | Vertex Pharmaceuticals (Europe) Limited (02907620) ↗ |
| FY2019 | Dec 31, 2019 | 4,798 | +30.7% | Vertex Pharmaceuticals (Europe) Limited (02907620) ↗ |
| FY2018 | Dec 31, 2018 | 3,670 | – | Vertex Pharmaceuticals (Europe) Limited (02907620) ↗ |
Breakdown
What makes up vertex Pharmaceuticals Limited
- Vertex Europe (UK) — Cost of sales ($M)9,070 · FY2025
- Vertex Europe (UK) — Gross profit ($M)3,714 · FY2025
- Vertex Europe (UK) — Research and development expenses ($M)300 · FY2025
- Vertex Europe (UK) — Administrative expenses ($M)2,137 · FY2025
- Vertex Europe (UK) — Other operating income ($M)16.5 · FY2025
- Vertex Europe (UK) — Operating profit ($M)1,293 · FY2025
- Vertex Europe (UK) — Interest receivable and similar income ($M)40.6 · FY2025
- Vertex Europe (UK) — Interest payable and similar expenses ($M)37.5 · FY2025
- Vertex Europe (UK) — Foreign exchange gain (loss) ($M)-7.20 · FY2025
- Vertex Europe (UK) — Profit before taxation ($M)1,292 · FY2025
- Vertex Europe (UK) — Tax on profit ($M)-292 · FY2025
- Vertex Europe (UK) — Profit for the financial year ($M)1,000 · FY2025
- Vertex Europe (UK) — Dividends paid to parent ($M)535 · FY2025
Cite this data
StockData. (2026). Vertex Pharmaceuticals Vertex Pharmaceuticals Limited ($M), annual FY2018–FY2025 [Data set]. Compiled from Vertex Pharmaceuticals SEC filings and investor materials. https://stockdatahq.com/stocks/vrtx/kpis/uk-eur-revenue
See every metric in the Vertex Pharmaceuticals KPI table. Data updated Nov 2, 2026.